FOLD Share Price Performance
US$6.99
-2.95 (-29.68%)
55.8% undervalued intrinsic discount
US$15.82
Fair Value
Price US$6.99
AnalystConsensusTarget US$15.82
Fair ValueUS$15.82
Share PriceUS$6.99
55.8% undervalued intrinsic discount
FOLD Community Narratives
AN
Fair Value US$15.82 55.8% undervalued intrinsic discount
Dimerix Collaboration Will Open Opportunities In US And Europe
0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
FOLD Community Fair Values
- US$15.82FV55.8% undervalued intrinsic discount21.39%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative23users have followed this narrative13 days ago author updated this narrative
Recent FOLD News & Updates
No updates
Amicus Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.12
- Gross Margin
- 90.37%
- Net Profit Margin
- -6.67%
- Debt/Equity Ratio
- 191.5%
Amicus Therapeutics, Inc. Competitors
About FOLD
- Founded
- 2002
- Employees
- 499
- CEO
- WebsiteView website
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a pullback of 4.7% in the Consumer Discretionary sector. As for the longer term, the market has actually risen by 23% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading